Resultados de longo prazo de estudo randomizado fase 2 | Elotuzumabe com pomalidomida e dexametasona para mieloma múltiplo recidivante/refratário.

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial – Journal of Clinical Oncology

Estudo original: Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma – New England Journal of Medicine